The role of COX-2 in intestinal cancer

Annals of the New York Academy of Sciences

Volumn 889, Issue , 1999, Pages 72-83

  Williams, Christopher ^a   Shattuck Brandt, Rebecca L ^a   DuBois, Raymond N ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 FLUOROPHENYL) 2 [(4 METHYLSULFONYL)PHENYL]CYCLOPENTENE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN; SALICYLATE SODIUM;

ALLELE; CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; ENZYME INDUCTION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; IMMEDIATE EARLY GENE; INTESTINE CANCER; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION;

EID: 0033403434     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb08725.x     Document Type: Conference Paper

References (76)

1. 1. Landis, S.H., T. Murray, S. Bolden & P.A. Wingo. 1999. Cancer statistics. CA Cancer J. Clin. 49: 8-31.
2. 2. Miyamoto, T., N. Ogino, S. Yamamoto & O. Hayaishi. 1976. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J. Biol. Chem. 251: 2629-2636.
3. 3. Miller, T.A. 1983. Protective effects of prostaglandins against gastric mucosal damage: Current knowledge and proposed mechanisms. Am. J. Physiol. 245: G601-623.
4. 4. Simmons, D.L., D.B. Levy, Y. Yannoni & R.L. Erikson. 1989. Identification of a phorbol ester-repressible v-src-inducible gene. Proc. Natl. Acad. Sci. USA 86: 1178-1182.
5. 5. Kujubu, D.A., B.S. Fletcher, B.C. Varnum, R.W. Lim & H.R. Herschman. 1991. TISIO, a phorbol ester tumor promoter-inducible MRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266: 12866-12872.
6. 6. Fu, J.Y., J.L. Masferrer, K. Seibert, A. Raz & P. Needleman. 1990. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. 265: 16737-16740.
7. 7. O'Sullivan, M.G., F.H. Chilton, E.M. Huggins & C.E. McCall. 1992. Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase. J. Biol. Chem. 267: 14547-14550.
8. 8. Lee, S.H., E. Soyoola, P. Chanmugam, S. Hart, W. Sun, H. Zhong, S. Liou, D. Simmons & D. Hwang. 1992. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J. Biol. Chem. 267: 25934-25938.
9. 9. Kujubu, D.A. & H.R. Herschman. 1992. Dexamethasone inhibits mitogen induction of the TISIO prostaglandin synthase/cyclooxygenase gene. J. Biol. Chem. 267: 7991-7994.
10. 10. Coyne, D.W., M. Nickols, W. Bertrand, and A.R. Morrison. 1992. Regulation of mesangial cell cyclooxygenase synthesis by cytokines and glucocorticoids. Am. J. Physiol. 263: F97-102.
11. 11. Jones, D.A., D.P. Carlton, T.M. McIntyre, G.A. Zimmerman & S.M. Prescott. 1993. Molecular cloning of human prostaglandin endoperoxide synthase type 11 and demonstration of expression in response to cytokines. J. Biol. Chem. 268: 9049-9054.
12. 12. Geng, Y., F. Blanco, M. Cornelisson & M. Lotz. 1995. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. J. Immunol. 155: 796-801.
13. 13. Ryseck, R.P., C. Raynoschek, H. Macdonald-Bravo, K. Dorfman, M.G. Mattei & R. Bravo. 1992. Identification of an immediate early gene, pghs-B, whose protein product has prostaglandin synthase/cyclooxygenase activity. Cell Growth & Differen. 3: 443-450.
14. 14. DeWitt, D.L. & E.A. Meade. 1993. Serum and glucocorticoid. regulation of gene transcription and expression of prostaglandin H synthase-1 and prostaglandin H synthase-2 isozymes. Arch. Biochem. Biophys. 306: 94-102.
15. 15. Hamasaki, Y., J. Kitzler, R. Hardman, P. Nettesheim & T.E. Eling. 1993. Phorbol ester and epidermal growth factor enhance the expression of two inducible prostaglandin H synthase genes in rat tracheal epithelial cells. Arch. Biochem. Biophys. 304: 226-234.
16. 16. DuBois, R.N., J. Awad, J. Morrow, L.J. Roberts & P.R. Bishop. 1994. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-α and phorbol ester. J. Clin. Invest. 93: 493-498.
17. 17. Riese, J., T. Hoff, A. Nordhoff, D.L. DeWitt, K. Resch & V. Kaever 1994. Transient expression of prostaglandin endoperoxide synthase-2 during mouse macrophage activation. J. Leukocyte Biol. 55: 476-482.
18. 18. Bazan, N.G., B.S. Fletcher, H.R. Herschman & P.K. Mukherjee. 1994. Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc. Natl. Acad. Sci. USA 91: 5252-5256.
19. 19. Kester, M., E. Coroneos, P.J. Thomas & M.J. Dunn. 1994. Endothelin stimulates prostaglandin endoperoxide synthase-2 MRNA expression and protein synthesis through a tyrosine kinase-signaling pathway in rat mesangial cells. J. Biol. Chem. 269: 22574-22580.
20. 20. Vane, J.R. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol. 231: 232-235.
21. 21. Non-Steroidal Anti-Inflammatory Drugs: Cyclooxygenase Inhibitors. 1997. Drug Market Development 8: 8-15.
22. 22. Pennisi, E. 1998. Building a better aspirin. Science 280: 1191-1192.
23. 23. Hial, V., Z. Horakova, F.E. Shaff & M.A. Beaven. 1976. Alteration of tumor growth by aspirin and indomethacin: Studies with two transplantable tumors in mouse. Eur. J. Pharmacol. 37: 367-376.
24. 24. Pollard, M. & P.H. Luckert. 1980. Indomethacin treatment of rats with dimethyl-hydrazine-induced intestinal tumors. Cancer Treat. Rep. 64: 1323-1327.
25. 25. Pollard, M. & P.H. Luckert. 1981. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 214: 558-559.
26. 26. Waddeel, W.R. & R.W. Loughry. 1983. Sulindac for polyposis of the colon. J. Surg. Oncol. 24: 83-87.
27. 27. Rigas, B., I.S. Goldman & L. Levine. 1993. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 122: 518-523.
28. 28. Bennett, A., A. Civier, C.N. Hensby, P.B. Melhuish & I.F. Stamford. 1987. Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues. Gut 28: 315-318.
29. 29. Eberhart, C.E., R.J. Coffey, A. Radhika, F.M. Giardiello, S. Ferrenbach & R.N. DuBois. 1994. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188.
30. 30. Sano, H., Y. Kawahito, R.L. Wilder, A. Hashiramoto, S. Mukai, K. Asai, S. Kimura, H. Kato, M. Kondo & T. Hla. 1995. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55: 3785-3789.
31. 31. Kutchera, W., D.A. Jones, N. Matsunami, J. Groden, T.M. McIntyre, G.A. Zimmerman, R.L. White & S.M. Prescott. 1996. Prostaglandin H synthase-2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. Proc. Natl. Acad. Sci. USA 93: 4816-4820.
32. 32. Kargman, S., G. O'Neill, P. Vickers, J. Evans, J. Mancini & S. Jothy. 1995. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 55: 2556-2559.
33. 33. Su, L.K., K.W. Kinzler, B. Vogelstein, A.C. Preisinger, A.R. Moser, C. Luongo, K.A. Gould & W.F. Dove. 1992. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256: 668-670.
34. 34. Singh, J., R. Hamid & B.S. Reddy. 1997. Dietary fat and colon cancer: Modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Res. 57: 3465-3470.
35. 35. Williams, C.W., C. Luongo, A. Radhika, T. Zhang, L.W. Lamps, L.B. Nanney, R.D. Beauchamp & R.N. DuBois. 1996. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 111: 1134-1140.
36. 36. DuBois, R.N., A. Radhika, B.S. Reddy & A.J. Entingh. 1996. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 110: 1259-1262.
37. Δ716 knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2). Cell 87: 803-809.
38. Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. 56: 710-714.
39. 39. Boolbol, S.K., A.J. Dannenberg, A. Chadburn, C. Martucci, X.J. Guo, J.T. Ramonetti, M. Abreu-Goris, H.L. Newmark, M.L. Lipkin, J.J. DeCosse & M.M. Bertagnoll. 1996. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56: 2556-2560.
40. 40. Chiu, C.H., M.F. McEntee & J. Whelan. 1997. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res. 57: 4267-4273.
41. 41. Beazer-Barclay, Y., D.B. Levy, A.R. Moser, W.F. Dove, S.R. Hamilton, B. Vogelstein & K.W. Kinzler. 1996. Sulindac suppresses tumorigenesis in the min mouse. Carcinogenesis 17: 1757-1760.
42. 42. Barnes, C.J. & M. Lee. 1998. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 114: 873-877.
43. 43. Mahmoud, N.N., S.K. Boolbol, A.J. Dannenberg, J.R. Mestre, R.T. Bilinski, C. Martucci, H.L. Newmark, A. Chadburn & M.M. Bertagnolli. 1998. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 19: 87-91.
44. 44. Rao, C.V., A. Rivenson, B. Simi, E. Zang, G. Kelloff, V. Steele & B.S. Reddy. 1995. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 55: 1464-1472.
45. 45. Piazza, G.A., D.S. Alberts, L.J. Hixson, N.S. Paranka, H. Li, T. Finn, C. Bogert, J.M. Guillen, K. Brendel, P.H. Gross, G. Sperl, J. Ritchie, R.W. Burt, L. Ellsworth, D.J. Ahnen & R. Pamukcu. 1997. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 57: 2909-2915.
46. 46. Samaha, H.S., G.J. Kelloff, V. Steele, C.V. Rao & B.S. Reddy. 1997. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenyl-hexyl isothiocyanate: Apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res. 57: 1301-1305.
47. 47. Reddy, B.S., C.V. Rao & K. Seibert. 1996. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 56: 4566-4569.
48. 48. Kawamori, T., C.V. Rao, K. Seibert & B.S. Reddy. 1998. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58: 409-412.
49. 49. Yoshimi, N., K. Kawabata, A. Hara, K. Matsunaga, Y. Yamada & H. More. 1997. Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn. J. Cancer Res. 88: 1044-1051.
50. 50. Pasricha, P.J., A. Bedi, K. O'Connor, A. Rashid, A.J. Akhtar, M.L. Zahurak, S. Piantadosi, S.R. Hamilton & F.M. Giardiello. 1995. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis [see comments]. Gastroenterology 109: 994-998.
51. 51. Shiff, S.J., L. Qiao, L.L. Tsai & B. Rigas. 1995. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest. 96: 491-503.
52. 52. Qiao, L., R. Hanif, E. Sphicas, S.J. Shiff & B. Rigas. 1998. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem. Pharmacol. 55: 53-64.
53. 53. Piazza, G.A., A.K. Rahm, T.S. Finn, B.H. Fryer, H. Li, A.L. Stoumen, R. Pamukcu & D.J. Ahnen. 1997. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 57: 2452-2459.
54. 54. Piazza, G.A., A.L. Rahm, M. Krutzsch, G. Sperl, N.S. Paranka, P.H. Gross, K. Brendel, R.W. Burt, D.S. Alberts, R. Pamukcu et al 1995. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55: 3110-3116.
55. 55. Goldberg, Y., I.I. Nassif, A. Pittas, L.L. Tsai, B.D. Dynlacht, B. Rigas & S.J. Shiff. 1996. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: Alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 12:893-901.
56. 56. Hixson, L.J., D.S. Alberts, M. Krutzsch, J. Einsphar, K. Brendel, P.H. Gross, N.S. Paranka, M. Baier, S. Emerson, R. Pamukcu et al. 1994. Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol. Biomarkers Prev. 3: 433-438.
57. 57. Hanif, R., A. Pittas, Y. Feng, M.I. Koutsos, L. Qiao, L. Staiano-Coico, S.I. Shiff & and B. Rigas. 1996. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52: 237-245.
58. 58. Qiao, L., S.J. Shiff & B. Rigas. 1997. Sulindac sulfide inhibits the proliferation of colon cancer cells: Diminished expression of the proliferation markers PCNA and Ki-67. Cancer Lett. 115: 229-234.
59. 59. Tsuji, S., S. Kawano, H. Sawaoka, Y. Takei, I. Kobayashi, K. Nagano, H. Fusamoto & T. Kamada. 1996. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins Leukotrienes Essent. Fatty Acids 55: 179-183.
60. 60. Sheng, H., J. Shao, S.C. Kirkland, P. Isakson, R. Coffey, J. Morrow, R.D. Beauchamp & R.N. DuBois. 1997. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 99: 2254-2259.
61. 61. Chan, T.A., P.J. Morin, B. Vogelstein & K.W. Kinzler. 1998. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. USA 95: 681-686.
62. 62. Tang, D.G., Y.Q. Chen & K.V. Honn. 1996. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc. Natl. Acad. Sci. USA 93: 5241-5246.
63. 63. Rüschoff, J., S. Wallinger, W. Dietmaier, T. Bocker, G. Brockhoff, F. Hofstddter & R. Fishel. 1998. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc. Natl. Acad. Sci. USA 95: 11301-11306.
64. 64. Taffet, S., J. Pace & S. Russell. 1981. Lymphokine maintains macrophage activation for tumor cell killing by interfering with the negative regulatory effect of prostaglandin E2. J. Immunol. 127: 121-124.
65. 65. Taffet, S. & S. Russell. 1981. Macrophage-mediated tumor cell killing: Regulation of expression of cytolytic activity by prostaglandin E. J. Immunol. 126: 424-427.
66. 66. Young, M., E. Wheeler & M. Newby. 1986. Macrophage-mediated suppression of natural killer cell activity in mice bearing Lewis lung carcinoma. J. Natl. Cancer Inst. 76: 745-750.
67. 67. Tsujii, M., S. Kawano, S. Tsuji, H. Sawaoka, M. Hori & R.N. DuBois. 1998. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716.
68. 68. Peleg, I.I., M.F. Lubin, G.A. Cotsonis, W.S. Clark & C.M. Wilcox. 1996. Longterm use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig. Dis. Sci. 41: 1319-1326.
69. 69. Giovannucci, E., E.B. Rimm, M.J. Stampfer, G.A. Colditz, A. Ascherio & W.C. Willett. 1994. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. 121: 241-246.
70. 70. Giovannucci, E., K.M. Egan, D.J. Hunter, M.J. Stampfer, G.A. Colditz, W.C. Willett & F.E. Speizer. 1995. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333: 609-614.
71. 71. Gann, P.H., J.E. Manson, R.J. Glynn, J.E. Buring & C.H. Hennekens. 1993. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J. Natl. Cancer Inst. 85: 1220-1224.
72. 72. Labayle, D., D. Fischer, P. Vielh, F. Drouhin, A. Pariente, C. Bories, O. Duhamel, M. Trousset & P. Attali. 1991. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635-639.
73. 73. Giardiello, F.M., S.R. Hamilton, A.J. Krush, S. Piantadosi, L.M. Hylind, P. Celano, S.V. Booker, C.R. Robinson & G.J. Offerhaus. 1993. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328: 1313-1316.
74. 74. Nugent, K.P., K.C. Farmer, A.D. Spigelman, C.B. Williams & R.K. Phillips. 1993. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg. 80: 1618-1619.
75. 75. Giardiello, F.M., E.W. Spannhake, R.N. DuBois, L.M. Hylind, C.R. Robinson, W.C. Hubbard, S.R. Hamilton & V.W. Yang. 1998. Prostaglandin levels in human colorectal mucosa: Effects of sulindac in patients with familial adenomatous polyposis. Dig. Dis. Sci. 43: 311-316.
76. 76. Pereira, M.A., L.H. Barnes, V.E. Steele, G.V. Kelloff & R.A. Lubet. 1996. Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats. Carcinogenesis 17: 373-376.